ASTRO Journals

Send us a textIn this podcast, PRO Section Editor, Minsun Kim, Ph.D., Professor, University of Texas Southwestern discusses Physics Patient Consults Program with Cassandra Stambaugh, Ph.D., Associate Professor, Tufts University and Ralph Ermoian, MD, Professor, University of Washington. Drs. Stambaugh and Ermoian pioneered the Physics Patient Consults Program at their institutions, bringing a wealth of experience and expertise. They will provide an overview of the program and discuss how to implement a simplified version in settings with limited resources, sharing insights into both the challenges and benefits it brings to patient care. This discussion is based on a paper in PRO titled "Feasibility and Benefits of a Simplified Physics Direct Patient Care Protocol." 

Send us a textEditor-in-Chief Sue Yom hosts Dr. Justin Smith, a Registrar in Queensland, Australia, and Dr. Lachlan McDowell, attending radiation oncologist at Princess Alexandra Hospital in Brisbane, Australia and Section Editor for Head and Neck Cancers at the journal. They were the first and last authors of “Red Journal Reviews: Typology, Methodology, and Standards.”

Send us a textEditor-in-Chief Sue Yom co-hosts with Dr. Claire Vanpouille-Box, Assistant Professor at Weill Cornell Medicine, Associate Editor in Biology at our journal, and expert on radiation and immunotherapy, interviewing Associate Professor Dr. Tsubasa Watanabe and Postdoctoral Scholar Dr. Genki Sato from the Institute for Integrated Radiation and Nuclear Science at Kyoto University, who were supervising and first authors on our recent new publication, “Conventional fractionated elective nodal irradiation preserves early antitumor immunity and efficacy compared to hypofractionated protocols”, joined by Dr. Jonathan Schoenfeld, Professor in the Department of Radiotherapy at Brigham and Women’s Hospital and supervising author of the accompanying editorial, “The Ongoing Challenge of Radiation-Immunotherapy Optimization: From Preclinical Insights to Clinical Practice.”

Send us a textEditor-in-Chief Sue Yom co-hosts with Dr. Sarah Milgrom, Associate Professor in the Department of Radiation Oncology at the University of Colorado and Section Editor for Lymphoma, interviewing Dr. Brad Hoppe, Professor in the Department of Radiation Oncology and Medical Director of Particle Therapy from Mayo Clinic Jacksonville, who was last author on “The Role of Radiation Therapy in the Management of Grey Zone Lymphoma,” first author on “Comparison of Contemporary Radiotherapy Approaches in Combined Modality Treatment on Pediatric High-Risk Classic Hodgkin Lymphoma Study: AHOD 1331,” and submitting author of a striking art cover called “Set in Bloom” created by his young adult patient Katherine Beatty, a survivor of Gray Zone lymphoma, as well as Dr. Belinda Campbell, Associate Professor and Deputy Director of Radiation Oncology at Peter MacCallum Cancer Centre and first author of “Radiation therapy utilization for primary cutaneous T-cell lymphoma is lowest amongst patients living in the most geographically accessible areas; an Australian study.”

Send us a textFor ASTRO 2025, our Editor-in-Chief Dr. Sue Yom hosts Dr. Minesh Mehta, Chief, Deputy Director and John and Mary Lou Dasburg Endowed Chair in Radiation Oncology at Baptist Health Miami Cancer Institute and first author of the article “Tumor Treating Fields (TTFields) therapy after stereotactic radiosurgery for brain metastases from non-small cell lung cancer: final results of the phase 3 METIS study”; Dr. Cliff Robinson, Professor and Chief of SBRT at Washington University in St. Louis, Thoracic Section Editor, and supervising author of Stereotactic Arrhythmia Radiotherapy (STAR) vs Repeat Catheter Ablation for High-Risk Refractory Ventricular Tachycardia: 3-Year Safety and Efficacy Outcomes; and Dr. Alexa Dang, Clinical Instructor in Radiation Oncology at BC Cancer in Vancouver and first author of Dosimetric Outcomes for Stereotactic Radiotherapy in Early-Stage Non-Small Cell Lung Cancer and Interstitial Lung Disease: A Secondary Analysis of the ASPIRE-ILD Trial.